| | Class 2 Device Recall ARCHITECT iGentimicin Reagent Kit |  |
| Date Initiated by Firm | April 24, 2020 |
| Date Posted | May 12, 2020 |
| Recall Status1 |
Open3, Classified |
| Recall Number | Z-2117-2020 |
| Recall Event ID |
85590 |
| 510(K)Number | K102699 |
| Product Classification |
Enzyme immunoassay, gentamicin - Product Code LCD
|
| Product | ARCHITECT iGentamicin Reagent Kit - Product Usage: The measurements obtained are used in the diagnosis and treatment of gentamicin overdose and in monitoring levels of gentamicin to help ensure appropriate therapy. |
| Code Information |
MODEL: 1P31-25 LOT NUMBERS: 04281BE00, 08510BE00 and 11221BE00 Shelf life per LOT: 04281BE00;2020-MAY-21 08510BE00; 2020-AUG-08 11221BE00;2020-NOV-18 |
| FEI Number |
3002809144
|
Recalling Firm/ Manufacturer |
Abbott Gmbh & Co. KG
Max-Planck-Ring 2
65205
Wiesbaden
Germany
|
| For Additional Information Contact | Dana Schmidt 224-667-8598 |
Manufacturer Reason for Recall | Abbott identified that samples tested for ARCHITECT STAT High Sensitive Troponin I and
STAT High Sensitivity Troponin I assays (LN 3P25 and LN 2R98) may show interaction when
processed directly after the ARCHITECT iGentamicin (LN 1P31) assay and patient results might be impacted. |
FDA Determined Cause 2 | Under Investigation by firm |
| Action | On April 24, 2020, Abbott issued a Product Correction letter to all customers who received shipments of the three impacted lots of ARCHITECT iGenatamicin Reagent kits. U.S. customers were sent the letter via FedEx priority overnight express. In the U.S., the customers will be requested to return to Abbott a Customer Reply Form acknowledging the receipt or a request for assistance. |
| Quantity in Commerce | 6087 Reagent Kits |
| Distribution | Worldwide distribution - US Nationwide distribution including in the states of AL, AZ, CA, CT, DE, FL, HI, IA, ID, IL, IN, KS, KY, LA, MA, ME, MI, MN, MO, MT, ND, NE, NJ, NV, NY, OH, OK, PA, RI, SC, TN,TX, UT, VA, VT, WA, WI, PR.
The countries of Algeria, Argentina, Australia, Austria, Bahrain, Barbados, Belarus, Belgium, Brazil, Brunei, Canada, Cayman Islands, Chile, China, Costa Rica, Croatia, Curacao, Czech Republic, Faroe Islands, France, Germany, Greece, Greenland, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Jordan, Kenya, Latvia, Lebanon, Lithuania, Malaysia, Mauritius, Namibia, Netherlands, New Zealand, Norway, Oman, Palestinian Territory, Philippines, Poland, Portugal, Republic of Yemen, Saudi Arabia, Slovakia, Slovenia, South Africa, South Korea, Spain, Sri Lanka, Sweden, Switzerland, Taiwan, Tunisia, UAE, United Kingdom and Uruguay. |
| Total Product Life Cycle | TPLC Device Report |
|
1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls. 2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall. 3 The manufacturer has initiated the recall and not all products have been corrected or removed. This record will be updated as the status changes.
|
| 510(K) Database | 510(K)s with Product Code = LCD
|
|
|
|